Last updated: April 24, 2026
Who Supplies Naloxegol Oxalate for Pharmaceutical Manufacturing?
Naloxegol oxalate is a small-molecule, mu-opioid receptor antagonist (PAMORA). Supply in the market is split between (1) branded and authorized commercial manufacturers for dosage forms (tablets) and (2) contract manufacturers and API supply chains that support generic and intermediate supply. The supplier landscape is also shaped by ongoing patent and regulatory status, which affects which firms can supply API and which supply dosage forms.
Which Companies Manufacture Naloxegol Oxalate Dosage Forms?
Global branded and commercial tablet suppliers (widely marketed):
- Bristol Myers Squibb (BMS): Original branded product supplier in major markets (naloxegol marketed as MOVANTIK).
- Bausch Health (as marketed by various local partners): Supplied through authorization and distribution networks in certain jurisdictions after entry for generics.
- Generic dosage-form manufacturers: Typically supply via locally authorized NDA/ANDA filings and contract packaging sites, with final product release tied to each regulator’s approval holder.
Because naloxegol oxalate is generally marketed as oral tablets, the practical “supplier” most buyers engage is often the finished-dose manufacturer or the authorized product holder in the target geography.
Key marketed product mapping
| Brand / Product |
Active |
Typical strength format |
Dominant commercial supplier(s) |
| MOVANTIK (naloxegol) |
naloxegol (often stated as naloxegol oxalate in regulatory dossiers for the salt form) |
12.5 mg and 25 mg |
Bristol Myers Squibb (brand owner and launch supplier) |
| Generic naloxegol tablets |
naloxegol (salt form) |
12.5 mg and 25 mg |
Multiple ANDA holders and contract manufacturers depending on country |
(Source framework: MOVANTIK branded approvals and supplier listings in regulatory and company disclosures.)
Who Supplies Naloxegol Oxalate API or Intermediates?
API supply for naloxegol oxalate is typically handled by a limited number of specialized small-molecule API manufacturers and custom synthesis/intermediate suppliers. In practical procurement, purchasers usually route through:
- API manufacturers listed in drug master files (DMFs) or included on regulatory submissions, and
- Contract development and manufacturing organizations (CDMOs) supporting salt formation and final crystallization.
A precise “who supplies naloxegol oxalate API” list depends on the jurisdiction, the DMF holders, and which authorization filings are active at procurement time. Public-facing supplier rosters are often incomplete or distributor-driven, so the most robust supplier identification uses the regulatory product dossier supply chain and DMF references.
How to Identify Supplier-Credible Naloxegol Oxalate Sources
For procurement and partner selection, buyers typically validate supplier status through four hard checkpoints:
- Regulatory listing of finished-dose manufacturer(s) in the approved product label and regulatory database for each country.
- DMF references for API and critical intermediates tied to ANDA/NDA approvals.
- GMP site evidence from inspection reports or regulator databases for the manufacturing site.
- Salt-form capability: ability to consistently manufacture naloxegol oxalate (crystal form controls, HPLC impurity profile, and residual solvent limits).
These checkpoints reduce the risk of non-equivalent supply (salt form drift, polymorph variation, or impurity threshold failures).
Market Supply Chain Structure
Naloxegol oxalate supply generally follows this chain:
- API (naloxegol base) + oxalic acid salt formation
- Crystallization and drying under controlled conditions
- Formulation into tablets (orol dispersible formats are not the dominant standard for naloxegol)
- Packaging and release testing by the approved finished-dose manufacturer
In contracts, CDMOs often sell either:
- the complete commercial manufacturing service (API + formulation + packaging), or
- API supply only with separate formulation by other partners.
What Buyers Should Expect in Supplier Capability Requirements
Supplier qualification for naloxegol oxalate usually includes:
Technical and quality items buyers screen
- Oxalate salt formation and crystal control documentation
- Impurity specification sets for naloxegol and salt-form impurities
- Stability program results for the salt and final tablets
- Residual solvents and polymorph controls
- Analytical method validation package (HPLC, DSC where applicable, XRPD where applicable)
Documentation and compliance items buyers screen
- GMP compliance status for the manufacturing site
- Batch record controls and change control history
- CoA completeness: assay, impurities, residual solvents, water content, particle attributes when relevant
Supplier Strategy by Buyer Type
Branded portfolio buyers
- Usually contract with established commercial suppliers already integrated into the global MOVANTIK supply chain.
- Qualification emphasizes long-run continuity and regulatory change notifications.
Generic and biosimilar-style parallel buyers (small molecule generics)
- Typically qualify API and salt formation first, then lock tablet formulation and packaging.
- Qualification focuses on BE strategy, impurity control, and stability alignment.
CDMO buyers
- Prioritize proven oxalate salt formation, tablet scale-up, and a record of regulatory submissions.
- Rely on a defined tech-transfer pack and a history of comparable molecules (opioid antagonist salts).
Key Takeaways
- Naloxegol oxalate is primarily supplied as approved oral tablets, with Bristol Myers Squibb as the original branded commercial supplier for MOVANTIK.
- API and salt supply is handled by specialized small-molecule API and salt-formation/CDMO networks; supplier identification must be validated via regulatory listings and DMF references.
- Supplier qualification should focus on oxalate salt formation control, impurity and stability specifications, and GMP site evidence tied to approved manufacturing.
FAQs
-
Is naloxegol sold as naloxegol oxalate in finished products?
Yes. Regulatory and label dossiers for naloxegol tablet products use the oxalate salt form for the commercial dosage form specification.
-
Who is the original supplier of MOVANTIK?
Bristol Myers Squibb is the branded originator and commercial supplier for MOVANTIK in major markets.
-
Can different companies supply the naloxegol oxalate tablets in generics?
Yes. Generic tablet supply is split across multiple ANDA/NDA-holding product makers and their contract manufacturing partners.
-
How do procurement teams validate API-supply credibility?
They validate via regulatory dossiers, DMF references, GMP site inspections, and CoA/analytical package requirements tied to naloxegol oxalate.
-
What manufacturing step differentiates naloxegol oxalate supply from naloxegol base supply?
The ability to form and control the oxalate salt (crystal form, impurities, and stability) consistently.
References (APA)
[1] U.S. Food and Drug Administration. (n.d.). MOVANTIK (naloxegol) prescribing information and drug approval history. FDA. https://www.accessdata.fda.gov
[2] European Medicines Agency. (n.d.). MOVANTIK EPAR (naloxegol). EMA. https://www.ema.europa.eu
[3] Bristol Myers Squibb. (n.d.). MOVANTIK product information. BMS. https://www.bms.com
